Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

AstraZeneca is Thursday's pick for IBD 50 Growth Stocks To Watch as the biopharmaceutical name is holding up relatively well ...

Harvey Jones is looking for UK stocks to add to this year's ISA, and decided to call in some assistance from artificial ...

UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare ...

Arvinas (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

In the FTSE All-Share, DFS Furniture jumped 11% or 13.8p to 145p after reporting an acceleration in order intake at the start ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Shares of Viking Therapeutics VKTX gained more than 11% on Wednesday after the company announced that it had signed a broad ...

H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.

NICE estimates that 1,000 women could benefit from Ryeqo, which can be taken once-daily up until the menopause.

As the FTSE 100 and FTSE 250 indices face downward pressure amid weaker-than-expected trade data from China, investors are closely watching for opportunities in undervalued stocks. In such a ...

Matt Britzman, senior equity analyst at Hargreaves Lansdown, said: "Halma, a FTSE 100 leader in life-saving technologies, has ...